ERBB2 and breast cancer: The prognosis for HER2+ BC has improved over the years with the development of specific drugs targeting this receptor, both monoclonal antibodies (trastuzumab and pertuzumab), as well as tyrosine kinase inhibitors (lapatinib, tucatinib) and drug-conjugated antibodies (ado-trastuzumab emtansine and trastuzumab deruxtecan), which are used in combination with chemotherapy or alone in different clinical scenarios [55].